# Brian Clevinger

> Brian Clevinger is a seed investor at Prolog Ventures backing Biotechnology and Genetics. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Prolog Ventures](https://shizune.co/investors/profile/prolog-ventures)
- Location: St Louis, United States
- Total investments: 7
- Last investment: Dec 2017
- Lead investor: 14%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/brian-clevinger-a22a615

Brian Clevinger is a seed investor at Prolog Ventures in St Louis focused on Biotechnology and Genetics. Brian is Co-Founder and General Partner of the Yield Lab Europe and led efforts on behalf of Yield Lab USA to come to Ireland. He is also Co-Founder and Managing Partner of Prolog Ventures, an early stage venture capital fund in the healthy living space, which includes agriculture, food and animal health.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 29% |
| Genetics | 1 | 14% |
| Health Care | 1 | 14% |
| Medical Device | 1 | 14% |
| Intellectual Property | 1 | 14% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 14% |
| Series A | 1 | 14% |
| Series D | 1 | 14% |
| Series E | 1 | 14% |
| Funding Round | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Agribody Technologies, Inc. | Agribody Technologies is a agricultural biotechnology company with patented technology that pinpoints and knocks down the gene that causes quick decay in perishable crops, resulting in 3X - 4X longer shelf life, more tolerance to stress, and up to 40% higher yields. CRISPR genome editing is the technical breakthrough enabling our precise novelplant trait development at low cost and high scalability, providing solutions for agricultural crop loss and food waste. We license and co-develop our technology. | $1.6M | Seed | Dec 25, 2017 |  |
| AirXpanders | AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implantsthat are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant. | $1M | Series E | Sep 03, 2014 |  |
| AirXpanders | AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implantsthat are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant. | $9M | Series E | Jun 03, 2013 |  |
| AirXpanders | AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implantsthat are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant. | $11M | Series D | Apr 20, 2012 |  |
| AirXpanders | AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implantsthat are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant. | $10.3M | Series D | Jan 23, 2012 |  |
| AirXpanders | AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implantsthat are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant. | $5.6M | Series A | Jan 22, 2007 |  |
| AirXpanders | AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implantsthat are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant. | $4M |  | Dec 29, 2006 |  |

7 of 7 investments shown.

## Co-investors
- [GBS Ventures](https://shizune.co/investors/profile/gbs-ventures) — VC Fund, 4 deals together
- [Vivo Capital](https://shizune.co/investors/profile/vivo-capital) — VC Fund, 2 deals together
- [Lateral Capital Management](https://shizune.co/investors/profile/lateral-capital-management) — VC Fund, 1 deal together

## About Prolog Ventures

VC Fund · St Louis, United States

Prolog backs companies that help all of us enjoy healthy lives in a healthy world

5 contacts available at Prolog Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Greg Johnson | Founder & Managing Director | https://shizune.co/investors/profile/greg-johnson-2 |
| Ilya Nykin | Co-founder & Managing Director | https://shizune.co/investors/profile/iliya-nykin |
| Brian Clevinger | Founder & Managing Director | https://shizune.co/investors/profile/brian-clevinger |
| Courtney Harris | Controller | https://shizune.co/investors/profile/courtney-harris |
| Dan Broderick | Venture Partner | https://shizune.co/investors/profile/dan-broderick |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Brian Clevinger invest in?

Brian Clevinger invests primarily in Biotechnology, Genetics and Health Care startups, most often at Seed and Series A stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Brian Clevinger last invest?

The most recent investment recorded for Brian Clevinger closed in Dec 2017. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co